Seung-Yul Lee1, Seung-Ho Hur1, Sang-Gon Lee1, Sang-Wook Kim1, Dong-Ho Shin1, Jung-Sun Kim1, Byeong-Keuk Kim1, Young-Guk Ko1, Donghoon Choi1, Yangsoo Jang1, Myeong-Ki Hong2. 1. From the Department of Cardiology, International St. Mary's Hospital, Incheon, Korea (S.-Y.L.); Department of Cardiology, Keimyung University College of Medicine, Daegu, Korea (S.-H.H.); Department of Cardiology, Ulsan University College of Medicine, Ulsan, Korea (S.-G.L.); Department of Cardiology, Chung-Ang University Medical Center, Seoul, Korea (S.-W.K.); Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University Health System, Seoul, Korea (D.-H.S., J.-S.K., B.-K.K., Y.-G.K., D.C., Y.J., M.-K.H.); and Cardiovascular Institute (D.-H.S., J.-S.K., B.-K.K., Y.-G.K., D.C., Y.J., M.-K.H.) and Severance Biomedical Science Institute (Y.J., M.-K.H.), Yonsei University College of Medicine, Seoul, Korea. 2. From the Department of Cardiology, International St. Mary's Hospital, Incheon, Korea (S.-Y.L.); Department of Cardiology, Keimyung University College of Medicine, Daegu, Korea (S.-H.H.); Department of Cardiology, Ulsan University College of Medicine, Ulsan, Korea (S.-G.L.); Department of Cardiology, Chung-Ang University Medical Center, Seoul, Korea (S.-W.K.); Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University Health System, Seoul, Korea (D.-H.S., J.-S.K., B.-K.K., Y.-G.K., D.C., Y.J., M.-K.H.); and Cardiovascular Institute (D.-H.S., J.-S.K., B.-K.K., Y.-G.K., D.C., Y.J., M.-K.H.) and Severance Biomedical Science Institute (Y.J., M.-K.H.), Yonsei University College of Medicine, Seoul, Korea. mkhong61@yuhs.ac.
Abstract
BACKGROUND: Despite the enhanced properties of the second-generation drug-eluting stent (DES), its association with neoatherosclerosis has not been sufficiently evaluated. Therefore, we sought to evaluate and compare neoatherosclerosis in second-generation DESs to first-generation DESs. METHODS AND RESULTS: A total of 212 DES-treated patients with >50% percent neointimal cross-sectional area stenosis were retrospectively enrolled from the Korean multicenter optical coherence tomography (OCT) registry. Within this population, 111 patients had a second-generation DES (40 zotarolimus, 36 everolimus, and 35 biolimus) and 101 patients had a first-generation (65 sirolimus and 36 paclitaxel) DES. Neoatherosclerosis on OCT was defined as neointima formation with the presence of lipids or calcification. OCT-determined neoatherosclerosis was identified in 27.4% (58/212) of all DES-treated lesions. The frequency of neoatherosclerosis increased with the stent age. Stent age was shorter in the second-generation DES group (12.4 months versus 55.4 months, P<0.001), and neoatherosclerosis was less frequently observed in that group (10.8% versus 45.5%, P<0.001). However, after adjusting for cardiovascular risk factors, chronic kidney disease (odds ratio, 4.113; 95% confidence interval, 1.086-15.575; P=0.037), >70 mg/dL of low-density cholesterol at follow-up OCT (odds ratio, 2.532; 95% confidence interval, 1.054-6.084; P=0.038), and stent age (odds ratio, 1.710; 95% confidence interval, 1.403-2.084; P<0.001) were all independent predictors for neoatherosclerosis, whereas the type of DES (first- versus second-generation) was not. Patients with neoatherosclerosis showed a higher rate of acute coronary syndrome at follow-up OCT (19.0% versus 3.9%, respectively, P=0.001). CONCLUSIONS: The second-generation DES is not more protective against neoatherosclerosis compared with the first-generation DES.
BACKGROUND: Despite the enhanced properties of the second-generation drug-eluting stent (DES), its association with neoatherosclerosis has not been sufficiently evaluated. Therefore, we sought to evaluate and compare neoatherosclerosis in second-generation DESs to first-generation DESs. METHODS AND RESULTS: A total of 212 DES-treated patients with >50% percent neointimal cross-sectional area stenosis were retrospectively enrolled from the Korean multicenter optical coherence tomography (OCT) registry. Within this population, 111 patients had a second-generation DES (40 zotarolimus, 36 everolimus, and 35 biolimus) and 101 patients had a first-generation (65 sirolimus and 36 paclitaxel) DES. Neoatherosclerosis on OCT was defined as neointima formation with the presence of lipids or calcification. OCT-determined neoatherosclerosis was identified in 27.4% (58/212) of all DES-treated lesions. The frequency of neoatherosclerosis increased with the stent age. Stent age was shorter in the second-generation DES group (12.4 months versus 55.4 months, P<0.001), and neoatherosclerosis was less frequently observed in that group (10.8% versus 45.5%, P<0.001). However, after adjusting for cardiovascular risk factors, chronic kidney disease (odds ratio, 4.113; 95% confidence interval, 1.086-15.575; P=0.037), >70 mg/dL of low-density cholesterol at follow-up OCT (odds ratio, 2.532; 95% confidence interval, 1.054-6.084; P=0.038), and stent age (odds ratio, 1.710; 95% confidence interval, 1.403-2.084; P<0.001) were all independent predictors for neoatherosclerosis, whereas the type of DES (first- versus second-generation) was not. Patients with neoatherosclerosis showed a higher rate of acute coronary syndrome at follow-up OCT (19.0% versus 3.9%, respectively, P=0.001). CONCLUSIONS: The second-generation DES is not more protective against neoatherosclerosis compared with the first-generation DES.
Authors: Lei Song; Gary S Mintz; Dong Yin; Myong Hwa Yamamoto; Chee Yang Chin; Mitsuaki Matsumura; Khady Fall; Ajay J Kirtane; Manish A Parikh; Jeffrey W Moses; Ziad A Ali; Richard A Shlofmitz; Akiko Maehara Journal: Int J Cardiovasc Imaging Date: 2017-03-09 Impact factor: 2.357
Authors: Ioannis Andreou; Saeko Takahashi; Masaya Tsuda; Koki Shishido; Antonios P Antoniadis; Michail I Papafaklis; Shingo Mizuno; Ahmet U Coskun; Shigeru Saito; Charles L Feldman; Elazer R Edelman; Peter H Stone Journal: Atherosclerosis Date: 2016-07-22 Impact factor: 5.162